HGH Fragment 176-191
HGH Fragment 176-191 is a C-terminal 16-amino acid fragment of human Growth Hormone (residues 176-191) that selectively stimulates lipolysis and inhibits lipogenesis through beta3-adrenergic receptor activation, independent of the GH receptor. Unlike full-length growth hormone, this fragment does not affect IGF-1 levels or insulin sensitivity, making it ideal for isolated adipose tissue metabolism research. The peptide targets visceral and subcutaneous fat depots, promoting triglyceride breakdown while suppressing new fat synthesis. This selectivity allows researchers to study lipolytic mechanisms and body composition changes without confounding growth-promoting or glucose-modulating effects.
HGH Fragment 176-191 is a C-terminal 16-amino acid fragment of human Growth Hormone (residues 176-191) that binds beta3-adrenergic receptors to stimulate lipolysis and inhibit lipogenesis independently of the GH receptor. Unlike full-length growth hormone, this fragment does not affect IGF-1 levels or insulin sensitivity, making it specifically valuable for adipose tissue metabolism research without systemic GH effects.
This synthetic peptide fragment represents the lipolytic domain of human growth hormone, retaining the fat-metabolizing properties while eliminating the growth-promoting and glucose-modulating effects of the full hormone. The fragment functions through beta3-adrenergic receptor activation, triggering intracellular signaling cascades that promote the breakdown of stored triglycerides into free fatty acids while simultaneously inhibiting new fat synthesis.
In research applications, HGH Fragment 176-191 demonstrates selective action on adipose tissue, particularly targeting visceral and subcutaneous fat depots. The mechanism involves enhanced lipolytic enzyme activity and reduced lipogenic enzyme expression, creating a net shift toward fat mobilization and away from fat storage. This makes it a valuable research tool for studying adipocyte metabolism, lipid partitioning, and body composition changes independent of growth hormone's anabolic effects.
The fragment's independence from GH receptor signaling means it does not elevate IGF-1, affect glucose metabolism, or produce the growth-promoting effects associated with full-length GH. This selectivity profile allows researchers to isolate and study lipolytic mechanisms without confounding variables from other GH-mediated pathways.
| Compound | MW / Formula | CAS No. | Sequence / Structure | Receptor / Target |
|---|---|---|---|---|
| HGH Fragment 176-191 | ~1817 g/mol | 135261-71-1 | 16-AA C-terminal GH fragment (residues 176-191) | Beta3-adrenergic receptor agonist; lipolysis stimulator |
The following compounds operate through distinct, non-overlapping mechanisms that complement this product's research pathways. Each is independently available from the General Peptide catalog.
This triple-blend combines two Growth Hormone Releasing Hormones (Tesamorelin, CJC-1295) with a selective ghrelin mimetic (Ipamorelin) to maximize pulsatile GH secretion. By targeting pituitary somatotrophs through distinct pathways, it synergi...
MOTS-c is a unique 16-amino acid peptide encoded by the mitochondrial genome rather than nuclear DNA. It functions as a potent metabolic regulator and "exercise mimetic" by translocating to the nucleus to activate AMPK, optimizing cellular ener...
Retatrutide (LY3437943) is an advanced 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple-agonist action coordinates appetite suppression, enhanced insulin dynamics, and increased hepat...
5-Amino-1MQ is a potent NNMT (Nicotinamide N-methyltransferase) inhibitor (MW 158.2 g/mol; C10H12N2) that enhances NAD+ biosynthesis and activates sirtuin pathways in adipose tissue. By blocking NNMT, it prevents SAM diversion toward nicotinami...
NAD+ is a vital dinucleotide coenzyme present in all living cells, central to cellular energy, DNA repair, and signaling. It fuels ATP production and acts as the rate-limiting substrate for Sirtuins, PARPs, and CD38 enzymes. Because NAD+ levels...